Related Experiment Video
Updated: May 2, 2026
12:21
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
15.4K
[Selective serotonin reuptake inhibitors and pregnancy]
Tahmineh Hassanzadeh1, Lars Henning Pedersen, Poul Videbech
1Bellisvej 11, 8464 Galten. tahmineh.has@gmail.com.
Ugeskrift for Laeger
|March 18, 2014
Summary
Selective serotonin reuptake inhibitors (SSRIs) are common for depression in pregnancy but may pose risks. However, these risks are low compared to the general population, and non-pharmacological options should be considered.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Neonatal Medicine
Context:
- Selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed for depression during pregnancy.
- Concerns exist regarding potential SSRI-related adverse outcomes in newborns.
- Balancing maternal mental health with fetal well-being is a critical clinical challenge.
Purpose:
- To review the current evidence on SSRI use in pregnancy.
- To evaluate the association between SSRI exposure and adverse neonatal outcomes.
- To provide evidence-based treatment recommendations for physicians managing depression in pregnant patients.
Summary:
- SSRIs are the primary pharmacological treatment for depression in pregnant individuals.
- Potential SSRI side effects include spontaneous abortion, cardiac malformations, preterm birth, low birthweight, persistent pulmonary hypertension, and neonatal withdrawal syndrome.
- The absolute risks of these side effects are low when compared to the general population, and non-pharmacological treatments are also recommended.
Impact:
- Informs clinical decision-making regarding SSRI use during pregnancy.
- Highlights the importance of risk-benefit assessment for SSRI therapy in pregnant patients.
- Encourages consideration of alternative, non-pharmacological interventions for depression in pregnancy.
Related Concept Videos
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
01:23Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
01:25Antidepressant Drugs: Overview
2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
928
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
928
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.8K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K